#GynCSM

#GynOnc #GYNCsm | Abdominal specimen retrieval in #endometrial cancer patients with large #uteri
⬇️
Learn more at the🔓link
journals.sagepub.com/share/EDBHID...

Mirvetuximab Soravtansine Plus Carboplatin Is Active in Platinum-Sensitive Ovarian Cancer | OncLive Mirvetuximab soravtansine plus carboplatin showed antitumor activity and a manageable safety profile in patients with recurrent platinum-sensitive ovarian cancer.

🧬 Mirvetuximab soravtansine + carboplatin demonstrated encouraging antitumor activity in platinum-sensitive ovarian cancer, supporting expansion of this ADC beyond the platinum-resistant setting. 📊
Read more ➡️ www.onclive.com/view/mirvetu... #gyncsm #oncology #SGOAM26

Tisotumab Vedotin With Carboplatin/Pembrolizumab ± Bevacizumab Shows Activity in Cervical Cancer | OncLive Tisotumab vedotin plus carboplatin & pembrolizumab ± bevacizumab achieved 65.8% ORR and 28-month median OS in first-line recurrent/metastatic cervical cancer.

💊 Promising data from #SGOAM26: Tisotumab vedotin + carboplatin + pembrolizumab ± bevacizumab delivered a 65.8% response rate and a median OS of 28 months in first-line recurrent/metastatic cervical cancer.

Learn more: 🔗 www.onclive.com/view/tisotum... #gyncsm #medtwitter #oncology

Sofetabart Mipitecan Displays Antitumor Activity in Recurrent Platinum-Resistant HGSOC | OncLive Sofetabart mipitecan elicited strong antitumor activity in recurrent platinum-resistant high-grade serous ovarian cancer.

🧬 Sofetabart mipitecan (LY4170156) demonstrated ~50% ORR and 78% disease control, with responses observed regardless of FRα expression and prior ADC exposure in early-phase data. 📊
Read more ➡️ www.onclive.com/view/sofetab...
#SGOAM26 #gyncsm

Trastuzumab Pamirtecan Elicits Responses in HER2-Expressing Advanced/Metastatic Endometrial Cancer | OncLive Trastuzumab pamirtecan achieved ~50% ORR in pretreated HER2-expressing endometrial cancer, earning FDA breakthrough designation per phase 1/2 trial data.

🔬 New data from #SGOAM26: The ADC trastuzumab pamirtecan hit a ~50% response rate in pretreated HER2-expressing endometrial cancer, with responses lasting nearly 10 months.

Learn more 🔗: www.onclive.com/view/trastuz...

#gyncsm #gynonc

Relacorilant Plus Nab-Paclitaxel Significantly Improves OS in Platinum-Resistant Ovarian Cancer | OncLive Relacorilant plus nab-paclitaxel cuts death risk by 35% and extends survival to 16 months in platinum-resistant ovarian cancer, per final ROSELLA trial data.

🚨Breakthrough in platinum-resistant ovarian cancer 🚨: Final OS data from the phase 3 ROSELLA trial show relacorilant plus nab-paclitaxel cuts the risk of death by 35%.

Learn more 🔗: www.onclive.com/view/relacor...

#SGOAM26 @news.upmc.com #gyncsm #gynonc #medtwitter

Dr Zsiros on the Use of Pembrolizumab/Paclitaxel/Bevacizumab for Ovarian Cancer | OncLive Emese Zsiros, MD, PhD, FACOG, discusses the FDA approval of pembrolizumab plus paclitaxel with or without pembrolizumab for PD-L1–positive ovarian cancer.

WATCH: Emese Zsiros, MD, PhD, FACOG, of @roswellpark.bsky.social, discusses the @fda.gov approval of pembrolizumab plus paclitaxel with or without pembrolizumab for PD-L1–positive ovarian cancer. #gyncsm #oncology
www.onclive.com/view/dr-zsir...

LinkedIn This link will take you to a page that’s not on LinkedIn

Those interested in #Socialmedia in health care, check our this project Previvorship www.previvorship.org) report on Social Media for Carriers of Hereditary Syndromes lnkd.in/eds-kMDm #gyncsm #lynchsyndrome #BRCA #bcsm

Why Do You Write? I just read a post Tiny Stories: Why I Write by my friend, Marie Ennis-O'Connor  She wrote her piece because of a prompt suggested by Linda...

Thanks Marie Ennis-O'Connor and Linda Caroll for the writing prompt that developed into this blog post.
Why I write...
womenofteal.blogspot.com/2026/03/why-... #gyncsm

Mark your calendars! The next chat takes place on April 7th during GLOBAL #AYACSM week!!!!

#AYACancerAwareness #BTSM #BCSM #LCSM #GYNCSM #ChildhoodCancer

Self #acupressure decreased cancer-related fatigue and improved quality of life compared with usual care for women with #ovariancancer. Published in @jamanetworkopen.com.

https://bit.ly/4rnqbBn

#gyncsm #cancerfatigue

GLP-1 Therapy Plus Progestin May Reduce Endometrial Cancer Risk in Some Patients In this cohort study, researchers aimed to examine endometrial cancer and hysterectomy patterns in patients who had endometrial hyperplasia or benign uterine pathology and were receiving progestins with or without GLP-1RAs or metformin.

For patients with endometrial hyperplasia or benign uterine pathology, receiving progestin in combination with #GLP1RA therapy is associated with a reduced risk of #endometrialCancer. Published in @jamanetworkopen.com.

https://bit.ly/4bOhdrR

#gyncsm #GLP1

Now open at UT Southwestern Simmons Cancer Center.

#gyncsm #clinicaltrial

A women in a fabulous suit giving a podium talk on brachytherapy for gyn cancer

Dr Onyinye Balogun at #ACRO2026 on best practices in #gyncsm #brachytherapy
including proper pain management during and after procedures. "we don't want our field trending on Tik tok for the wrong reason"

Pan-Canadian research team dedicated to improving the lives of children with cancer and their families In 2022, the Canadian Institutes of Health Research (CIHR) launched a $23 million team-grant opportunity to support the establishment of a national pediatric cancer consortium that would change the wa...

Check out our new study re: #ChildhoodCancer on this #WorldCancerDay👇

www.mcgill.ca/nursing/arti...

#BCSM #BTSM #AYACSM #GYNCSM @healthsciences.mcgill.ca

Q2: What challenges have you faced recently in using #SocialMedia for #AYACancer/ #Cancer advocacy?

#AYACSM #LCSM #BTSM #BCSM #GYNCSM

[#AYACSM] Our next public conversation is taking place tomorrow (Tues, Feb. 3rd) night at 8 PM EST. Join us as we discuss living in a digital world and how that impacts our adolescent and young adults (AYA) cancer advocacy initiatives!

#Oncology #Cancer #AYACancer #BTSM #BCSM #GYNCSM #LCSM #HPM

SCORES: Suvemcitug Shows Promise in Platinum-Resistant Ovarian Cancer Adding the VEGF antibody suvemcitug to chemotherapy significantly improved survival for patients with ovarian cancer who progressed followed

Adding the VEGF antibody suvemcitug to chemotherapy significantly improved survival for patients with #ovariancancer who progressed followed platinum-based chemotherapy. Published in @natcancer.nature.com.

https://bit.ly/3NRPHj3

#gyncsm

Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement Gynecologic malignancies accounted for ∼15 % of new cancer cases and cancer survivors in 2022. Advances in cancer care are expected to improve outcomes, and the growth in survivorship is expected to i...

Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement - Gynecologic Oncology www.gynecologiconcology-online.net/article/S009... #gyncsm

Genetic tumor syndromes in female cancer: insights into inherited cancer predisposition and clinical implications - Archives of Gynecology and Obstetrics A relevant proportion of malignancies predominantly or exclusively affecting women, including breast and gynecologic cancers, is attributable to hereditary tumor syndromes, profoundly impacting cancer...

This review provides a comprehensive overview of #hereditarycancer predisposing to breast and gynecologic malignancies, with a focus on genetic basis, associated cancer risks, and implications for clinical management.

#bcsm #gyncsm #genetics #womenshealth #cancerresearch #medsky

I said goodbye to my best friend, Amber, yesterday. She was my best survivorship therapy. #gyncsm womenofteal.blogspot.com/2026/01/beyo...

In Ovarian Cancer, Interval Debulking Surgery Leads to Fewer Complications, Does Not Affect Survival In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who received interval debulking surgery compared to primary debulking surgery.

In patients with advanced #ovariancancer, undergoing interval debulking surgery results in similar survival outcomes as primary debulking surgery.

https://bit.ly/4qFQ12r

#gyncsm

In Ovarian Cancer, Interval Debulking Surgery Leads to Fewer Complications, Does Not Affect Survival In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who received interval debulking surgery compared to primary debulking surgery.

In patients with advanced #ovariancancer, undergoing interval debulking surgery results in similar survival outcomes as primary debulking surgery.

https://bit.ly/4qFQ12r

#gyncsm

Join Our Remote Breast Cancer Study Participate in a groundbreaking study to advance breast cancer treatment. Receive a genetic ancestry report. Open to US residents 18+.

Research Study for the Genetics of Breast Cancer - Open now led by Dr. Tara Matise ( @facingourrisk.bsky.social
and Rutgers University) Rutgers Genetics Coordinating Center
bcstudy.org/FORCE
Open in the US to 18yrs +, having had cancer or not, with Internet access. #gyncsm #bcsm #lcsm

Tamoxifen Use May Increase Endometrial Cancer Risk in  Premenopausal Patients with Breast Cancer - Oncology Nurse Advisor In this retrospective cohort study of a large population in Belgium, researchers aimed to examine endometrial cancer risk in patients with breast cancer who received tamoxifen.

In premenopausal women with non-metastatic #breastcancer, use of tamoxifen may nearly double the risk of #endometrialcancer. Presented in a poster at @sabcs.bsky.social #SABCS25, from @cancertherapyadv.bsky.social.

https://bit.ly/4aPZUpV

#bcsm #gyncsm

Coming up this Tuesday!! Our first #AYACSM chat of 2026!!

ALL are welcome from our other #OncSky communities: #BTSM #BCSM #LCSM #GYNCSM #ChildhoodCancer

#TYACancer #AYACancer

The Essential but Often Complex Role of Numbers and Measurements in Oncology, Continued | OncLive Maurie Markman, MD, discusses the essential but often complex role associated with the interpretation of numbers and measurements in oncology.

The Essential but Often Complex Role of Numbers and Measurements in Oncology, Continued @cityofhopecologne.bsky.social
#gyncsm #oncology
www.onclive.com/view/the-ess...

Reminder to let me know if you want to be part of the #AYACSM calendar reminders! Next chat is this Tuesday!

Welcoming all from the #BTSM, #LCSM, #BCSM, #OncSky, #GYNCSM etc. communities!!

Adding Atezolizumab to Standard Therapy Fails to Improve Survival in Recurrent Ovarian Cancer - Oncology Nurse Advisor Investigators evaluated atezolizumab combined with bevacizumab and non–platinum-based chemotherapy for patients with recurrent ovarian cancer.

Atezolizumab in combination with bevacizumab and non-platinum-based chemotherapy did not significantly improve survival in patients with recurrent #ovarianCancer. Published in @ascopost.bsky.social Journal of Clinical Oncology and @cancertherapyadv.bsky.social.

https://bit.ly/49sianV

#gyncsm

Fuzuloparib Extends PFS as Maintenance Therapy for Advanced Ovarian Cancer FZOCUS-1 assessed the safety and efficacy of fuzuloparib alone and in combination with apatinib for patients with newly diagnosed or advanced ovarian cancer.

Fuzuloparib monotherapy extended PFS by more than 15 months for patients with #ovariancancer compared with placebo. Published in @americancancersoc.bsky.social CA Cancer Journal.

https://bit.ly/4sbJ22Q

#gyncsm